← back to search

Alejandro Berlín

University of Toronto · CA
Area of research
Pulmonary and Respiratory Medicine · Radiation
Research interest
Research interests include Prostate Cancer Diagnosis and Treatment, Prostate Cancer Treatment and Research, Advanced Radiotherapy Techniques, and Radiopharmaceutical Chemistry and Applications.
h-index
34
citations
7,029
works
439
NIH funding
primary concept
Medicine
email

Recent publications

A practical framework for operationalising responsible and equitable artificial intelligence in health care: tackling bias, inequity, and implementation challenges
The Lancet Digital Health 2026cited by 0position: middledoi
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Journal of Clinical Oncology 2025cited by 21position: middledoi
The landscape of N6-methyladenosine in localized primary prostate cancer
Nature Genetics 2025cited by 17position: middledoi
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation
Cancer Cell 2025cited by 16position: middledoi
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials
Annals of Oncology 2025cited by 12position: middledoi
oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer − a systematic review and expert consensus
Radiotherapy and Oncology 2025cited by 3position: middledoi
In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor–microenvironment interactions
Nature Genetics 2024cited by 23position: middledoi
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer
Radiotherapy and Oncology 2024cited by 20position: middledoi
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
The Lancet Oncology 2023cited by 241position: middledoi
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
International Journal of Radiation Oncology*Biology*Physics 2023cited by 32position: middledoi
Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer
NEJM Evidence 2023cited by 29position: middledoi
The influence of the “cancer” label on perceptions and management decisions for low-grade prostate cancer
JNCI Journal of the National Cancer Institute 2023cited by 15position: firstdoi
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
Journal of Clinical Oncology 2022cited by 240position: middledoi
Low-Grade Prostate Cancer: Time to Stop Calling It Cancer
Journal of Clinical Oncology 2022cited by 86position: middledoi
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer
JAMA Oncology 2022cited by 45position: middledoi
Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus
International Journal of Radiation Oncology*Biology*Physics 2022cited by 25position: middledoi
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression
Nature Cell Biology 2021cited by 529position: middledoi
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
European Urology 2021cited by 99position: middledoi
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
JAMA Network Open 2021cited by 33position: middledoi
Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features
JAMA Network Open 2021cited by 30position: middledoi
A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer
European Urology 2020cited by 205position: middledoi
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases
JAMA Oncology 2020cited by 96position: middledoi
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate
JAMA Oncology 2020cited by 90position: middledoi
Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier
Prostate Cancer and Prostatic Diseases 2020cited by 26position: middledoi
ONECUT2 is a driver of neuroendocrine prostate cancer
Nature Communications 2019cited by 241position: middledoi
048 Canadian TrueNTH Sexual Health and Rehabilitation eClinic (SHAReClinic): Online Education and Support for Prostate Cancer Patients and their Partners
The Journal of Sexual Medicine 2019cited by 0position: middledoi
Genomic hallmarks of localized, non-indolent prostate cancer
Nature 2017cited by 636position: middledoi
Spatial genomic heterogeneity within localized, multifocal prostate cancer
Nature Genetics 2015cited by 486position: middledoi
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
The Lancet Oncology 2014cited by 351position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Felix Y. Feng · Polytechnique Montréal3 papers (2021–2023)Daniel E. Spratt · Drexel University3 papers (2020–2023) · 2 papers (2022–2023)Andrew J. Vickers · Nashville Oncology Associates2 papers (2022–2023)Amar U. Kishan · University of Colorado Denver2 papers (2021–2023)Gladell P. Paner · University of Chicago2 papers (2022–2023)Scott E. Eggener · Veracyte (United States)2 papers (2022–2023)Phuoc T. Tran · University of Maryland, Baltimore2 papers (2021–2023)Melvin L.K. Chua · National Cancer Centre Singapore2 papers (2020–2023)Matthew R. Cooperberg · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2022–2023)Kenneth J. Pienta · University of Baltimore1 papers (2021–2021)Yoshiya Yamada · Memorial Sloan Kettering Cancer Center1 papers (2020–2020)Channing J. Paller · University Hospitals Seidman Cancer Center1 papers (2021–2021)Antonio Finelli · Collaborative Group (United States)1 papers (2019–2019)Christopher J.D. Wallis · Teikyo University1 papers (2023–2023)Zhihui Liu · Hangzhou Medical College1 papers (2023–2023)Jorge García · Case Western Reserve University1 papers (2023–2023)Jennifer L. Robinson · University of Maryland, College Park1 papers (2019–2019) · 1 papers (2026–2026)Gustavo Nader Marta · Instituto do Câncer do Estado de São Paulo1 papers (2020–2020)